SKIP - A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects With Advanced or Metastatic Colorectal Carcinoma Receiving Panitumumab. [Eine doppelblinde, placebo-kontrollierte, randomisierte, multizentrische Phase II Studie zur Behandlung von Hauttoxizitäten bei Patienten mit metastasierten kolorektalen Karzinomen, die Panitumumab erhalten]
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Doxycycline (Primary) ; Panitumumab
- Indications Bacterial infections; Skin infections
- Focus Therapeutic Use
- Acronyms SKIP
Most Recent Events
- 14 Jul 2014 Biomarkers information updated
- 17 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Jul 2012 Actual initiation date (2 May 2011) added as reported by European Clinical Trials Database.